SK Bioscience

At a glance

SK Bioscience filed 54 disclosures in the last 12 months, including 5 insider, 4 earnings, 2 5% holder, 1 contract and 1 buyback. The most recent key filing was on Aug 10: Operating profit: loss narrowed (-₩37.4B → -₩15.7B). Revenue ₩156B, down 3.8% YoY.

Revenue for 2025 was ₩651B, up 143.5% on 2024. It made an operating loss of ₩124B. Debt was 45% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩324B and operating loss of ₩60.3B.

The 2025 annual report lists 1,129 employees with an average tenure of 4.5 years and average pay of ₩67.8M, #784 of 2,191 listed companies by average pay. Its 8 directors and auditors were paid ₩460M each on average. It paid no cash dividend for 2025. SK케미칼(주) and related parties held 66.53% at year end.

Of 2 recent 5%+ holder reports, 1 raised and 1 cut a stake; the largest stake reported was 66.73% on Mar 27.

From the 2025 annual report

Staff: 1,129 (644 men, 485 women), of whom 192 on fixed-term contracts. Total pay for the year: ₩76.3B. Directors and auditors: 8, paid ₩3.7B in total.

No cash dividend was paid for 2025.

Largest shareholder

SK케미칼(주) holds 66.37%; with 2 related parties the group holds 66.53% of common shares at year end (from 66.55% at the start of the year).

Individuals paid ₩500M or more

Auditor: 한영회계법인 · opinion: Unqualified.

Rankings: Revenue growth #13 of 1,376

Source: 2025 annual business report (DART). How figures are combined

New contracts, last 12 months

1 new supply contract worth 4% of the revenue stated in the filings.

Amended amounts replace the originals. Subsidiary contracts and terminations are excluded.

Financial summary

5%+ holder reports